Potential therapeutic targets for Mpox: the evidence to date
Siddappa N. Byrareddy(Nebraska Medical Center), Kamal Singh(Karolinska Institutet), Arpan Acharya(University of Nebraska Medical Center), Kalicharan Sharma(Indo Soviet Friendship College of Pharmacy), Christian L. Lorson(University of Missouri), Kaylee M. Klaustermeier(University of Missouri), Shrikesh Sachdev(University of Missouri), Athreya S. Reddy(University of Missouri)
Cited by 20
Related Papers
Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies
|Journal of Autoimmunity|2021|234
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic
|Journal of Medicinal Chemistry|2018|181
Quinoline‐derivatives as privileged scaffolds for medicinal and pharmaceutical chemists: A comprehensive review
|Chemical Biology & Drug Design|2022|92